Imunon (NASDAQ:IMNN) General Counsel Susan Eylward Sells 11,800 Shares

Imunon, Inc. (NASDAQ:IMNN) General Counsel Susan Eylward sold 11,800 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $1.75, for a total transaction of $20,650.00. Following the completion of the sale, the general counsel directly owned 2,896 shares of the company’s stock, valued at $5,068. The trade was a 80.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Imunon Stock Performance

IMNN opened at $1.80 on Tuesday. The firm’s fifty day moving average is $2.31 and its two-hundred day moving average is $2.99. The firm has a market cap of $7.56 million, a PE ratio of -0.35 and a beta of 1.95. Imunon, Inc. has a twelve month low of $1.70 and a twelve month high of $11.19.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38. Equities analysts forecast that Imunon, Inc. will post -3.46 EPS for the current fiscal year.

Institutional Trading of Imunon

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNN. Armistice Capital LLC bought a new stake in shares of Imunon in the fourth quarter worth $1,017,000. Riverview Capital Advisers LLC increased its stake in Imunon by 193.3% in the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock valued at $176,000 after buying an additional 22,649 shares during the last quarter. Finally, DRW Securities LLC increased its stake in Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after buying an additional 3,803 shares during the last quarter. 4.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Maxim Group set a $10.00 target price on Imunon and gave the company a “buy” rating in a research note on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Imunon has a consensus rating of “Hold” and an average target price of $10.00.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.